TWI648057B - 用於緩解經前症候群以及經痛之組合物 - Google Patents
用於緩解經前症候群以及經痛之組合物 Download PDFInfo
- Publication number
- TWI648057B TWI648057B TW103122873A TW103122873A TWI648057B TW I648057 B TWI648057 B TW I648057B TW 103122873 A TW103122873 A TW 103122873A TW 103122873 A TW103122873 A TW 103122873A TW I648057 B TWI648057 B TW I648057B
- Authority
- TW
- Taiwan
- Prior art keywords
- ginseng fruit
- composition
- extract
- present disclosure
- ginseng
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 86
- 206010036618 Premenstrual syndrome Diseases 0.000 title claims abstract description 33
- 208000005171 Dysmenorrhea Diseases 0.000 title claims abstract description 18
- 235000008434 ginseng Nutrition 0.000 claims abstract description 180
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 176
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 176
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 161
- 239000000284 extract Substances 0.000 claims abstract description 132
- 235000013305 food Nutrition 0.000 claims abstract description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 11
- 241000208340 Araliaceae Species 0.000 claims abstract 9
- 229930182494 ginsenoside Natural products 0.000 claims description 24
- PWAOOJDMFUQOKB-WCZZMFLVSA-N ginsenoside Re Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@](C)(CCC=C(C)C)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O PWAOOJDMFUQOKB-WCZZMFLVSA-N 0.000 claims description 23
- AOGZLQUEBLOQCI-UHFFFAOYSA-N ginsenoside-Re Natural products CC1OC(OCC2OC(OC3CC4(C)C(CC(O)C5C(CCC45C)C(C)(CCC=C(C)C)OC6OC(CO)C(O)C(O)C6O)C7(C)CCC(O)C(C)(C)C37)C(O)C(O)C2O)C(O)C(O)C1O AOGZLQUEBLOQCI-UHFFFAOYSA-N 0.000 claims description 21
- 239000004480 active ingredient Substances 0.000 claims description 19
- PYXFVCFISTUSOO-HKUCOEKDSA-N (20S)-protopanaxadiol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@H]([C@@](C)(O)CCC=C(C)C)[C@H]4[C@H](O)C[C@@H]3[C@]21C PYXFVCFISTUSOO-HKUCOEKDSA-N 0.000 claims description 16
- PYXFVCFISTUSOO-UHFFFAOYSA-N betulafolienetriol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC(C(C)(O)CCC=C(C)C)C4C(O)CC3C21C PYXFVCFISTUSOO-UHFFFAOYSA-N 0.000 claims description 16
- SWQINCWATANGKN-UHFFFAOYSA-N protopanaxadiol Natural products CC(CCC=C(C)C)C1CCC2(C)C1C(O)CC1C3(C)CCC(O)C(C)(C)C3CCC21C SWQINCWATANGKN-UHFFFAOYSA-N 0.000 claims description 16
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 14
- 239000011707 mineral Substances 0.000 claims description 14
- 235000010755 mineral Nutrition 0.000 claims description 14
- SHCBCKBYTHZQGZ-DLHMIPLTSA-N protopanaxatriol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2[C@@H](O)C[C@@]3(C)[C@]4(C)CC[C@H]([C@](C)(O)CCC=C(C)C)[C@H]4[C@H](O)C[C@@H]3[C@]21C SHCBCKBYTHZQGZ-DLHMIPLTSA-N 0.000 claims description 14
- BBEUDPAEKGPXDG-UHFFFAOYSA-N protopanaxatriol Natural products CC(CCC=C(C)C)C1CCC2(C)C1C(O)CC3C4(C)CCC(O)C(C)(C)C4C(O)CC23C BBEUDPAEKGPXDG-UHFFFAOYSA-N 0.000 claims description 14
- 229940088594 vitamin Drugs 0.000 claims description 14
- 229930003231 vitamin Natural products 0.000 claims description 14
- 235000013343 vitamin Nutrition 0.000 claims description 14
- 239000011782 vitamin Substances 0.000 claims description 14
- 229940089161 ginsenoside Drugs 0.000 claims description 13
- 235000010208 anthocyanin Nutrition 0.000 claims description 11
- 239000004410 anthocyanin Substances 0.000 claims description 11
- 229930002877 anthocyanin Natural products 0.000 claims description 11
- 150000004636 anthocyanins Chemical class 0.000 claims description 10
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 10
- 229930182490 saponin Natural products 0.000 claims description 10
- 150000007949 saponins Chemical class 0.000 claims description 10
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 6
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 6
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 6
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 4
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 claims description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 3
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 3
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 3
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 3
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 3
- 229930003268 Vitamin C Natural products 0.000 claims description 3
- 229930003448 Vitamin K Natural products 0.000 claims description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 3
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 3
- 239000011575 calcium Substances 0.000 claims description 3
- 229910052791 calcium Inorganic materials 0.000 claims description 3
- 229960000304 folic acid Drugs 0.000 claims description 3
- 235000019152 folic acid Nutrition 0.000 claims description 3
- 239000011724 folic acid Substances 0.000 claims description 3
- 229910052742 iron Inorganic materials 0.000 claims description 3
- 239000011777 magnesium Substances 0.000 claims description 3
- 229910052749 magnesium Inorganic materials 0.000 claims description 3
- 229960003512 nicotinic acid Drugs 0.000 claims description 3
- 235000001968 nicotinic acid Nutrition 0.000 claims description 3
- 239000011664 nicotinic acid Substances 0.000 claims description 3
- 229940055726 pantothenic acid Drugs 0.000 claims description 3
- 235000019161 pantothenic acid Nutrition 0.000 claims description 3
- 239000011713 pantothenic acid Substances 0.000 claims description 3
- 239000011574 phosphorus Substances 0.000 claims description 3
- 229910052698 phosphorus Inorganic materials 0.000 claims description 3
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims description 3
- 239000011591 potassium Substances 0.000 claims description 3
- 229910052700 potassium Inorganic materials 0.000 claims description 3
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims description 3
- 235000019155 vitamin A Nutrition 0.000 claims description 3
- 239000011719 vitamin A Substances 0.000 claims description 3
- 235000019154 vitamin C Nutrition 0.000 claims description 3
- 239000011718 vitamin C Substances 0.000 claims description 3
- 235000019168 vitamin K Nutrition 0.000 claims description 3
- 239000011712 vitamin K Substances 0.000 claims description 3
- 150000003721 vitamin K derivatives Chemical class 0.000 claims description 3
- 229940045997 vitamin a Drugs 0.000 claims description 3
- 229940046010 vitamin k Drugs 0.000 claims description 3
- 239000011701 zinc Substances 0.000 claims description 3
- 229910052725 zinc Inorganic materials 0.000 claims description 3
- 239000000469 ethanolic extract Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 abstract description 20
- 230000000694 effects Effects 0.000 abstract description 19
- 240000004371 Panax ginseng Species 0.000 description 172
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 35
- 238000000605 extraction Methods 0.000 description 25
- 238000000034 method Methods 0.000 description 25
- 239000003960 organic solvent Substances 0.000 description 20
- 238000002360 preparation method Methods 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 235000002789 Panax ginseng Nutrition 0.000 description 13
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 11
- 238000001035 drying Methods 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 238000010992 reflux Methods 0.000 description 9
- 229940107131 ginseng root Drugs 0.000 description 8
- 239000007937 lozenge Substances 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- 230000037396 body weight Effects 0.000 description 7
- 239000003981 vehicle Substances 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 235000009508 confectionery Nutrition 0.000 description 6
- 238000000855 fermentation Methods 0.000 description 6
- 230000004151 fermentation Effects 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 230000002996 emotional effect Effects 0.000 description 5
- -1 for example Substances 0.000 description 5
- 230000005906 menstruation Effects 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000004375 Dextrin Substances 0.000 description 4
- 229920001353 Dextrin Polymers 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 235000019425 dextrin Nutrition 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 235000015218 chewing gum Nutrition 0.000 description 3
- 229940112822 chewing gum Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000013365 dairy product Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 238000003306 harvesting Methods 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 238000007602 hot air drying Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 239000007901 soft capsule Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 2
- 206010006298 Breast pain Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- QDVZZZBBPRFPDG-DHJOXOLYSA-N Cyanin chloride Chemical compound [Cl-].O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=[O+]C1=CC(O)=C2)C=3C=C(O)C(O)=CC=3)=CC1=C2O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 QDVZZZBBPRFPDG-DHJOXOLYSA-N 0.000 description 2
- 208000006662 Mastodynia Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 235000013334 alcoholic beverage Nutrition 0.000 description 2
- 230000003178 anti-diabetic effect Effects 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 235000015895 biscuits Nutrition 0.000 description 2
- 235000008429 bread Nutrition 0.000 description 2
- 235000012970 cakes Nutrition 0.000 description 2
- 235000013736 caramel Nutrition 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- VEVZSMAEJFVWIL-UHFFFAOYSA-O cyanidin cation Chemical compound [O+]=1C2=CC(O)=CC(O)=C2C=C(O)C=1C1=CC=C(O)C(O)=C1 VEVZSMAEJFVWIL-UHFFFAOYSA-O 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 229940068517 fruit extracts Drugs 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- 235000015243 ice cream Nutrition 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000002175 menstrual effect Effects 0.000 description 2
- 235000012149 noodles Nutrition 0.000 description 2
- 230000016087 ovulation Effects 0.000 description 2
- 230000027758 ovulation cycle Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 239000000186 progesterone Substances 0.000 description 2
- 229960003387 progesterone Drugs 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- FIRXFHJQGIIJDB-UHFFFAOYSA-N 1-methyl-2,3-dihydroindole Chemical compound C1=CC=C2N(C)CCC2=C1 FIRXFHJQGIIJDB-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- GPKJNSIFVWMEEI-UHFFFAOYSA-N 17-bromo-2,5,8,11,14-pentaoxabicyclo[13.4.0]nonadeca-1(15),16,18-triene Chemical compound O1CCOCCOCCOCCOC2=CC(Br)=CC=C21 GPKJNSIFVWMEEI-UHFFFAOYSA-N 0.000 description 1
- COAWNPJQKJEHPG-UHFFFAOYSA-N 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-1lambda^{4}-chromen-1-ylium chloride Chemical compound [Cl-].[O+]=1C2=CC(O)=CC(O)=C2C=C(O)C=1C1=CC=C(O)C(O)=C1 COAWNPJQKJEHPG-UHFFFAOYSA-N 0.000 description 1
- KQIKOUUKQBTQBE-UHFFFAOYSA-N 3,5,7-trihydroxy-2-(4-hydroxy-3,5-dimethoxyphenyl)-1lambda^{4}-chromen-1-ylium chloride Chemical compound [Cl-].COC1=C(O)C(OC)=CC(C=2C(=CC=3C(O)=CC(O)=CC=3[O+]=2)O)=C1 KQIKOUUKQBTQBE-UHFFFAOYSA-N 0.000 description 1
- DIRROHKULXIUCB-DHJOXOLYSA-N 3,5-Bis(glucosyloxy)-4',7-dihydroxyflavylium chloride Chemical compound [Cl-].O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=[O+]C1=CC(O)=C2)C=3C=CC(O)=CC=3)=CC1=C2O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DIRROHKULXIUCB-DHJOXOLYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010054196 Affect lability Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 206010006313 Breast tenderness Diseases 0.000 description 1
- 241001107116 Castanospermum australe Species 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 240000004385 Centaurea cyanus Species 0.000 description 1
- 235000005940 Centaurea cyanus Nutrition 0.000 description 1
- 244000018436 Coriandrum sativum Species 0.000 description 1
- 235000002787 Coriandrum sativum Nutrition 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 241000208152 Geranium Species 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000000982 Malva neglecta Species 0.000 description 1
- 235000000060 Malva neglecta Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000017657 Menopausal disease Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 244000150738 Sesamum radiatum Species 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000021017 Weight Gain Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003217 anti-cancerogenic effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000004594 appetite change Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000021279 black bean Nutrition 0.000 description 1
- 235000007215 black sesame Nutrition 0.000 description 1
- 208000024330 bloating Diseases 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 235000021329 brown rice Nutrition 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000007766 cera flava Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- MZZBPDKVEFVLFF-UHFFFAOYSA-N cyanazine Chemical compound CCNC1=NC(Cl)=NC(NC(C)(C)C#N)=N1 MZZBPDKVEFVLFF-UHFFFAOYSA-N 0.000 description 1
- 235000007336 cyanidin Nutrition 0.000 description 1
- YTMNONATNXDQJF-QSLGVYCOSA-N cyanidin 3-O-beta-D-galactoside chloride Chemical compound [Cl-].O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CC2=C(O)C=C(O)C=C2[O+]=C1C1=CC=C(O)C(O)=C1 YTMNONATNXDQJF-QSLGVYCOSA-N 0.000 description 1
- ADZHXBNWNZIHIX-XYGAWYNKSA-N cyanidin 3-O-rutinoside chloride Chemical compound [Cl-].O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(=[O+]C3=CC(O)=CC(O)=C3C=2)C=2C=C(O)C(O)=CC=2)O1 ADZHXBNWNZIHIX-XYGAWYNKSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- FFNDMZIBVDSQFI-UHFFFAOYSA-N delphinidin chloride Chemical compound [Cl-].[O+]=1C2=CC(O)=CC(O)=C2C=C(O)C=1C1=CC(O)=C(O)C(O)=C1 FFNDMZIBVDSQFI-UHFFFAOYSA-N 0.000 description 1
- 235000021185 dessert Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002876 effect on osteoporosis Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 235000008446 instant noodles Nutrition 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960002067 keracyanin chloride Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 229920003175 pectinic acid Polymers 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000003495 polar organic solvent Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000005186 women's health Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本揭示案係關於一種含有人參果萃取物的組合物。本揭示案亦係關於一種用於緩解經前症候群及經痛的組合物,該組合物含有人參果萃取物。根據本揭示案的組合物展現緩解或改良經前症候群之症狀之效果且因此可用作醫藥組合物或食品組合物。
Description
本揭示案係關於一種含有人參果萃取物的組合物。
人參(Panax ginseng C.A.Meyer)係屬於五加科人參屬的植物。早在兩千年前,韓國、中國、日本等就已根據經驗將人參用作草藥以預防疾病及延年益壽。迄今已知的人參之效果及功效包括對中樞神經系統的作用、抗致癌作用、抗癌作用、免疫調節作用、抗糖尿病作用、肝功能改良效果、改良心血管障礙的作用、抗動脈粥樣硬化作用、血壓控制作用、改善更年期障礙的作用、對骨質疏鬆症的效果、抗壓作用、抗疲勞作用、抗氧化作用、抗衰老作用等(The Recent Korean Ginseng:Constituents and Effects,Korea Ginseng and Tobacco Research Institute,56-112,1996)。
人參皂苷係人參中的代表性生理活性成分,均勻分佈於人參之地面及地下部分中。然而,眾所周知,人參皂苷之含量及組合物取決於各個部分(諸如根、葉、果實等)而變化(Attele AS等人,Biochem Pharmacol,58;1685-1693,
1999)。
經前症候群(Premenstrual syndrome;PMS)係指與女性月經週期相關的情緒及身體症狀,發生於排卵後的月經週期期間的生育年齡女性中(American Psychiatric A,American Psychiatric Association Washington DC,1994,ACGO Practice B.Obstetrics and Gynecology 95(1),1-9,2000)。80%的女性患有PMS之輕度身體及精神症狀(Hylan TR等人,Journal of Women’s Health and Gender Based Medicine 8(8),1043-1052,1999)。並且,24%-32%的生育年齡女性患有中度或重度症狀(Campell EM等人,Journal of Reproductive Medicine 42(10)637-646,1997)。該等症狀因限制女性活動而導致巨大的社交與經濟損失。
常見身體、行為及情緒症狀如下:(Freeman EW,Psychoneuroendocrinology 28,25-37,2003)。
目前,很少有人知道人參果中所包含的特定成分及其與緩解經前症候群及經痛相關的功能。
(專利文件1)KR0171408 B1.
American Psychiatric A, American Psychiatric Association Washington DC, 1994.
ACGO Practice B. Obstetrics and Gynecology 95(1), 1-9, 2000.
Hylan TR等人,Journal of Women`s Health and Gender Based Medicine 8(8), 1043-1052, 1999.
Campell EM等人,Journal of Reproductive Medicine 42(10) 637-646, 1997.
Freeman EW,Psychoneuroendocrinology 28, 25-37, 2003.
Bea EA等人,Biological & Pharmaceutical Bulletin 28(10), 1903-1908, 2005.
本揭示案係針對提供一種含有人參果的組合物,該組合物提供一種對於人類健康的新穎用途,亦即,緩解經前症候群及經痛。
在一般態樣中,本揭示案提供一種用於緩解經前症候群及經痛的組合物,該組合物含有人參果萃取物作為活性成分。
在另一個一般態樣中,本揭示案提供一種用於緩解及改良經前症候群的組合物,該組合物含有人參果萃取物作為活性成分。
根據本揭示案含有人參果萃取物的組合物可有效緩解及改良經前症候群及經痛。
因此,根據本揭示案的組合物可廣泛用於食品及藥品領域。
第1圖圖示分析根據本揭示案的人參果萃取物與用於對照的人參根部萃取物之人參皂苷組份之結果。
第2圖圖示比較服用根據本揭示案的人參果萃取物之前與之後的經前症候群之結果。
在下文中,將詳細描述本揭示案。
在一態樣中,本揭示案提供一種用於改良或緩解經前症候群及經痛的組合物,作為活性成分,該組合物含有人參皂苷Re或含有Re的人參果萃取物。
在一示例性實施例中,本揭示案可係關於一種用於改良或緩解經前症候群及經痛的組合物,包括向需要改良或緩解經前症候群及經痛之個體施予人參皂苷Re或含有Re的人參果萃取物。特定而言,在本揭示案之一示例性實施例中,給藥可遵循本揭示案所描述之給藥方法或給藥劑量。
在一示例性實施例中,本揭示案可係關於一種用於改良或緩解經前症候群及經痛之人參皂苷Re或含有Re的人參果萃取物之用途。
在一示例性實施例中,本揭示案可係關於一種用於改良或緩解經前症候群及經痛之人參皂苷Re或含有Re的人
參果萃取物。
在本揭示案之一示例性實施例中,經前症候群係指月經前反復發生的情緒、行為及身體症狀。常見症狀可包括身體症狀(諸如乳房疼痛、鼓脹、頭痛等)及心理症狀(諸如情緒不穩定、抑鬱、不安、攻擊性等)。該等症狀在排卵後變得逐漸嚴重,在月經前的一周到達極點,且一旦月經開始後,該等症狀在數日內消失。
在本揭示案之一示例性實施例中,經前症候群可包括情緒症狀(諸如注意力不集中、攻擊性、抑鬱、不安等)及身體症狀(諸如水腫、乳房疼痛、消化失調、頭痛、背痛等),且根據本揭示案的組合物可為用於改良或緩解此類症狀的組合物。
本揭示案中所使用之人參果展現出與常用之人參根部在組份及組合物上的差異。
在本揭示案中,與人參根部相比,人參果可含有更多包括維生素在內的礦物質組份。又,人參果含有比人參根部更多的人參皂苷及人參皂苷之組合物亦有所不同。
在一示例性實施例中,由於人參果萃取物可含有比原人參二醇(protopanaxadiol;PD)人參皂苷(諸如人參皂苷Rb1、Rb2、Rc、Rd等)更多的原人參三醇(protopanaxatriol;PT)人參皂苷(諸如人參皂苷Re、Rg1、Rg2等),本揭示案可提供不同的效果。舉例而言,據報告,人參果展現出比人參根部更好的抗糖尿病效果(Dey L.等人,Phytomedicine,10;600-605,2003)。
在本揭示案中,人參皂苷可從人參果中獲得。
經前症候群之確切原因尚未被完全理解且可基於生物學現象給出解釋。儘管據報告經前症候群不與特定激素水平關聯,但是認為孕酮的減少、雌激素水平的變化及雌激素/孕酮比率的變化是可能原因(Kim TH,Journal of Soonchunhyang Medical Science 14(3),79-84,2009)。大體而言,認為PMS及經痛起因於上述因素以及環境因素之組合。
大量存在於人參果萃取物中的人參皂苷Re之化學結構如化學式1所示。
在本揭示案之一示例性實施例中,以人參果萃取物之總重量計,可含有5-30重量%或10-25重量%之量的人參皂苷Re。特定而言,在本揭示案之一示例性實施例中,以人參果萃取物之總重量計,人參果萃取物中含有以下量的人參皂苷Re:0.1重量%或更多、1重量%或更多、5重量%或更多、
7重量%或更多、10重量%或更多、12.5重量%或更多、13重量%或更多、15重量%或更多、17重量%或更多、20重量%或更多、23重量%或更多、25重量%或更多、27重量%或更多、30重量%或更多、35重量%或更多、或者40重量%或更多,及45重量%或更少、40重量%或更少、35重量%或更少、30重量%或更少、25重量%或更少、23重量%或更少、20重量%或更少、17重量%或更少、15重量%或更少、13重量%或更少、12.5重量%或更少、10重量%或更少、7重量%或更少、5重量%或更少、或者1重量%或更少。
在本揭示案之一示例性實施例中,人參果萃取物可具有0.1-1.5或0.4-0.9之原人參二醇(PD)人參皂苷對原人參三醇(PT)人參皂苷重量比率(PD/PT)。特定而言,在本揭示案之一示例性實施例中,原人參二醇(PD)人參皂苷對原人參三醇(PT)人參皂苷重量比率(PD/PT)可為0.1或更大、0.15或更大、0.2或更大、0.25或更大、0.3或更大、0.35或更大、0.4或更大、0.45或更大、0.5或更大、0.55或更大、0.6或更大、0.65或更大、0.69或更大、0.7或更大、0.73或更大、0.75或更大、0.8或更大、0.85或更大、0.9或更大、0.95或更大、或者1.0或更大,及1.5或更小、1.3或更小、1.0或更小、0.95或更小、0.9或更小、0.85或更小、0.8或更小、0.75或更小、0.73或更小、0.7或更小、0.69或更小、0.65或更小、0.6或更小、0.55或更小、0.5或更小、0.45或更小、0.4或更小、0.3或更小、0.2或更小或者0.1或更小。特定而言,在本揭示案之一示例性實施例中,原人參二醇(PD)人參皂苷對原人
參三醇(PT)人參皂苷重量比率(PD/PT)可為0.69或0.73。
由於人參果萃取物可含有大量維生素、礦物質、人參皂苷、花青素等,根據本揭示案之一示例性實施例的組合物可改良及緩解經前症候群(PMS)及經痛之症狀。
在本揭示案之一示例性實施例中,可藉由一方法製備人參果萃取物,該方法包含:(a)預處理人參果;及(b)用水或有機溶劑萃取經預處理之人參果。
在步驟(a)中,人參果可為新鮮人參果及可在日光或熱風下乾燥人參果之果肉及果皮。
特定而言,在本揭示案之一示例性實施例中,預處理可為乾燥人參果及乾燥方法可為熟習此項技術者常用以乾燥植物果實(諸如人參果)之方法,但沒有特定限制。特定而言,在本揭示案之一示例性實施例中,乾燥可為日曬乾燥、熱風乾燥、蒸發乾燥、噴霧乾燥或冷凍乾燥,更特定言之為日曬乾燥或熱風乾燥。更特定言之,在本揭示案之一示例性實施例中,預處理可包括:從人參果中分離及移除籽;及乾燥人參果之果肉及果皮。
在本揭示案之一示例性實施例中,該方法可進一步包括:在步驟(b)後,(c)濃縮所得萃取物。
進一步地,在步驟(b)中,可藉由在室溫下使用水或有機溶劑在回流下萃取經乾燥之人參果來製備人參果萃取物,接著在減小的壓力下濃縮。有機溶劑可為乙醇。
在本揭示案之一示例性實施例中,濃縮可為減壓濃
縮,但可使用為熟習此項技術者所熟知的任何方法而沒有特定限制。特定而言,在本揭示案之一示例性實施例中,濃縮可為減壓濃縮,且可在40-45℃下執行減壓濃縮。
在本揭示案之一示例性實施例中,該方法可進一步包括:在步驟(c)後,(d)移除油溶性組份。
在本揭示案之一示例性實施例中,藉由將人參果萃取物溶解於水中及隨後添加二乙醚,可使用分液漏斗移除油溶性組份。
在本揭示案之一示例性實施例中,該方法可進一步包括:在步驟(d)後,(e)藉由添加有機溶劑萃取已移除油溶性組份之萃取物。
特定而言,在本揭示案之一示例性實施例中,步驟(e)可包括:在藉由添加有機溶劑萃取萃取物後,濃縮萃取物以獲得人參果萃取物。
在本揭示案之一示例性實施例中,可藉由以下步驟製備人參果萃取物,舉例而言:從新鮮人參果中移除籽及藉由熱風乾燥乾燥人參果之果肉及果皮;及藉由添加2-4L之水或乙醇在室溫下的回流下萃取500g至1.5kg之經乾燥之人參果,過濾所得萃取物及隨後於40-45℃減壓濃縮萃取物,但不限於此。
在本揭示案中,可藉由(例如)熱水萃取、加熱萃取、冷水萃取、回流萃取、回流冷卻萃取、超聲萃取等執行萃取。可使用熟習此項技術者所常用之任何萃取方法而無限制。儘管可在室溫下執行萃取,但為了更加有效之萃取,可
在加熱狀態下執行萃取,特定而言在約40-100℃下,更特定言之在約80℃下,但不受限於此。特定而言,萃取時間可為約2-4小時,更特定言之約3小時,但不受限於此。萃取時間可取決於諸如萃取溶劑、萃取溫度等狀態而變化。特定而言,當將水用作溶劑時,可在90-100℃執行萃取;當將乙醇用作溶劑時,可在65-70℃執行萃取。可反復萃取一次以上以獲得較高產出率之活性成分,特定而言為1-5次,更特定言之為3次。特定而言,在本揭示案之一示例性實施例中,可在室溫下執行回流萃取。
在本揭示案之一示例性實施例中,以萃取物之總重量計,礦物質可為以下之一或更多者:至少4000mg/100g之鉀、至少600mg/100g之鈣、至少40mg/100g之鐵、至少150mg/100g之磷、至少250mg/100g之鎂及至少140mg/100g之鋅。
在本揭示案之一示例性實施例中,礦物質可包括4000mg/100g至10g/100g之鉀、600mg/100g至5g/100g之鈣、40mg/100g至1g/100g之鐵、150mg/100g至1g/100g之磷、250mg/100g至5g/100g之鎂及140mg/100g至5g/100g之鋅,但不受限於此。
在本揭示案之一示例性實施例中,以萃取物之總重量計,維生素可為以下之一或更多者:至少150μg/100g之維生素A、至少8mg/100g之維生素B1、至少5mg/100g之維生素B2、至少8mg/100g之維生素B6、至少3mg/100g之維生素C、至少180μg/100g之維生素K、至少3.5mg/100
g之菸鹼酸、至少4mg/100g之泛酸及至少250μg/100g之葉酸。
在本揭示案之一示例性實施例中,維生素可包括150μg/100g至20mg/100g之維生素A、8mg/100g至5g/100g之維生素B1、5mg/100g至5g/100g之維生素B2、8mg/100g至5g/100g之維生素B6、3mg/100g至5g/100g之維生素C、180μg/100g至20mg/100g之維生素K、3.5mg/100g至5g/100g之菸鹼酸、4mg/100g至5g/100g之泛酸及250μg/100g至20mg/100g之葉酸,但不受限於此。
在本揭示案之一示例性實施例中,以萃取物之總重量計,組合物可含有至少20ppm,特定而言20-1000ppm之花青素,但不受限於此。
根據本揭示案之一示例性實施例的組合物可取決於組合物類型含有0.01-100重量%之人參皂苷Re或含有Re的人參果萃取物。特定而言,在本揭示案之一示例性實施例中,以組合物之總重量計,可含有以下量的人參皂苷Re或含有Re的人參果萃取物:0.01重量%或更多、0.1重量%或更多、1重量%或更多、5重量%或更多、10重量%或更多、20重量%或更多、30重量%或更多、40重量%或更多、50重量%或更多、60重量%或更多、70重量%或更多、80重量%或更多、90重量%或更多、或者99重量%或更多,及100重量%或更少。
在本揭示案之一示例性實施例中,以人參果萃取物之總重量計,人參果萃取物可含有至少20重量%之粗皂素。
特定而言,在本揭示案之一示例性實施例中,以人參果萃取物之總重量計,人參果萃取物可含有20重量%或更多、22重量%或更多、24重量%或更多、26重量%或更多、28重量%或更多、30重量%或更多、31重量%或更多、32重量%或更多、33重量%或更多、35重量%或更多、37重量%或更多、40重量%或更多、或者45重量%或更多,及50重量%或更少、46重量%或更少、44重量%或更少、42重量%或更少、40重量%或更少、38重量%或更少、36重量%或更少、34重量%或更少、32重量%或更少、30重量%或更少、28重量%或更少、26重量%或更少、或者24重量%或更少之粗皂素。
在本揭示案之一示例性實施例中,人參果萃取物可為水或C1-C6低級醇萃取物。特定而言,在本揭示案之一示例性實施例中,C1-C6低級醇可為選自由甲醇、乙醇、丙醇、丁醇及己醇組成之群組中的一或更多者,但並不受限於此。
在本揭示案之一示例性實施例中,人參果萃取物可為人參果之粗皂素萃取物。特定而言,在本揭示案之一示例性實施例中,人參果之粗皂素萃取物可藉由從人參果萃取物中移除油溶性組份及隨後用有機溶劑萃取來獲得。特定而言,有機溶劑可為低極性之有機溶劑,諸如(例如)己烷、二氯甲烷、乙酸乙酯或丁醇。因此,在本揭示案之一示例性實施例中,人參果之粗皂素萃取物可為已用低極性之有機溶劑萃取之水溶性餾分。
在本揭示案之一示例性實施例中,組合物可以選自由粉末劑、顆粒劑、錠劑、軟膠囊或硬膠囊及飲品組成之群
組中的調配物形式存在,但並不受限於此。
在本揭示案中,「萃取物」係指從天然產物中萃取之任何物質,無關於萃取方法、萃取溶劑、所萃取組份或萃取類型。又,萃取物包括可藉由加工或以其他方式處理所得物質而獲得的物質。特定而言,萃取物之加工或處理可為發酵或酶促處理。因此,在本揭示案中,術語萃取物被廣義使用,包括發酵產物、濃縮產物及乾燥產物。特定而言,萃取物可為發酵產物。
在本揭示案中,「人參果萃取物」係指從人參果中萃取之任何物質,無關於萃取方法、萃取溶劑、所萃取組份或萃取類型。人參果萃取物包括藉由熱、酸、鹼、酶等處理物質而獲得的物質。又,人參果萃取物包括可藉由加工或以其他方式處理人參果之所萃取組份而獲得的物質。特定而言,人參果萃取物之加工或處理可為發酵或酶促處理。因此,在本揭示案中,人參果萃取物可為人參果萃取物之發酵產物。又,人參果萃取物可為新鮮人參果或經乾燥之人參果之萃取物。在本揭示案中,可用於萃取的新鮮人參果、經乾燥之人參果或經加工之人參果(例如,發酵產物、乾燥粉末等)在組合物方面可為類似或相同。因此,具有類似或相同組合物的新鮮人參果、經乾燥之人參果或人參果之其他加工產物可提供與本揭示案中所描述之人參果萃取物相同的效果及用途。
在本揭示案之一示例性實施例中,「人參果」可以萃取物、新鮮人參果、經粉碎之人參果、經乾燥之人參果、
人參果之經乾燥粉末或人參果之發酵產物形式存在,但不受限於此。本揭示案在如何獲得人參果方面不受限制。可培育或商業購買人參果。在本揭示案中,人參果不一定需要被乾燥及可為任何形式,只要適合於萃取人參果之活性成分。在本揭示案中,新鮮人參果可指示在收穫後尚未經乾燥或以其他方式加工的人參果。
在本揭示案之一示例性實施例中,可藉由一方法製備人參果萃取物,該方法包括(1)用水、有機溶劑或上述之組合萃取人參果。
在本揭示案之一示例性實施例中,該方法可進一步包括:在步驟(1)後,(2)濃縮所得萃取物。
在本揭示案之一示例性實施例中,該方法可進一步包括:在步驟(2)後,(3)從所濃縮萃取物中移除油溶性組份。
在本揭示案之一示例性實施例中,步驟(3)可進一步包括:在移除油溶性組份後,用有機溶劑萃取。
在本揭示案之一示例性實施例中,該方法可進一步包括:在步驟(3)後,(4)濃縮由步驟(3)所產生的產物。特定而言,由步驟(3)所產生的產物可為已移除油溶性組份之濃縮產物或移除油溶性組份後用有機溶劑萃取之萃取物。
在本揭示案之一示例性實施例中,可藉由一方法製備人參果萃取物,該方法包括:(i)用水、有機溶劑或上述之組合萃取人參果;以及(ii)從所得萃取物中移除油溶性組份。
在本揭示案之一示例性實施例中,該方法可進一步
包括:在步驟(ii)後,(iii)用有機溶劑萃取。
在本揭示案之一示例性實施例中,該方法可進一步包括:在步驟(iii)後,(iv)濃縮萃取物。
在本揭示案之一示例性實施例中,水可為蒸餾水或純水,及有機溶劑可為選自由以下組成之群組中的一或更多者:例如,C1-C6低級醇(諸如甲醇、乙醇或正丁醇)、丙酮、醚、乙酸乙酯、二乙醚、甲基乙基酮、氯仿、己烷及二氯甲烷,但不受限於此。特定而言,在本揭示案之一示例性實施例中,用於萃取人參果的有機溶劑可為水、乙醇或上述之組合,及用於移除油溶性組份的有機溶劑可為比用於萃取人參果之有機溶劑極性更小的有機溶劑(例如,正丁醇)。
在本揭示案之一示例性實施例中,可藉由在室溫的回流下使用水或有機溶劑萃取人參果及減壓濃縮所得萃取物來製備人參果萃取物。有機溶劑可為乙醇。並且,在本揭示案之一示例性實施例中,可將組合物製備成錠劑、丸劑、小丸劑、膠囊劑、顆粒劑、粉末劑、軟膏劑、飲品、注射劑等形式之醫藥組合物或食品組合物。
在一示例性實施例中,本揭示案提供一種含有人參皂苷Re或人參果萃取物作為活性成分的醫藥組合物,根據常用方法製備該醫藥組合物。特定而言,可藉由與媒劑混合或用媒劑稀釋活性成分或將活性成分封裝於適宜媒劑中來製備醫藥組合物。當將媒劑用作稀釋劑時,該媒劑可為固體、半固體或液體物質,該媒劑充當活性成分的載體、賦形劑或介質。因此,醫藥組合物可為錠劑、丸劑、粉末劑、藥囊、酒
劑、懸浮液、乳液、溶液、糖漿、氣霧劑、軟明膠膠囊或硬明膠膠囊、無菌注射劑、無菌粉末劑等形式。
適宜媒劑、賦形劑或稀釋劑之實例可包括乳糖、右旋糖、蔗糖、山梨糖醇、甘露醇、矽酸鈣、纖維素、甲基纖維素、微晶纖維素、聚乙烯吡咯烷酮(polyvinylpyrrolidone)、水、羥基苯甲酸甲酯(methyl hydroxybenzoate)、羥基苯甲酸丙酯(propyl hydroxybenzoate)、滑石、硬脂酸鎂及礦物油。醫藥組合物可進一步含有填充劑、抗凝劑、潤滑劑、濕潤劑、芳香劑、乳化劑、防腐劑等。可將本揭示案之醫藥組合物製備成調配物,在向哺乳動物施予後,該調配物可根據技術中所熟知之方法提供活性成分之快速、連續或受控釋放。
可經由各種途徑施予本揭示案之醫藥組合物,該等途徑包括口服、經皮、皮下、靜脈、腹膜、肌內注射、局部及電離子透入途徑。特定而言,可局部或口服施予醫藥組合物。
對於人類受試者,活性成分之一般每日給藥劑量為1mg至100g/kg體重,特定而言50mg至80g/kg體重、100mg至60g/kg體重、200mg至50g/kg體重、300mg至40g/kg體重、500mg至35g/kg體重或者1g至30g/kg體重,並且可每日一次或數次給藥。然而,應將理解,考慮許多相關因素決定活性成分之實際給藥劑量,該等因素包括待治療之疾病、給藥路徑、年齡、性別及患者體重、疾病嚴重性等。因此,上述給藥劑量不藉由任何手段限制本揭示案之範疇。
在一示例性實施例中,本揭示案提供一種含有人參
皂苷Re或人參果萃取物作為活性成分的食品組合物,根據常用方法製備該食品組合物。
本揭示案之食品組合物在食品類型方面不特別受限制。舉例而言,可將本揭示案之組合物添加至諸如飲品、肉類、香腸、麵包、餅乾、年糕、巧克力、糖果、點心、糖果甜點、披薩、速食面、其他麵條、口香糖、包括冰淇淋的乳製品、湯、飲料、酒精飲料、維生素錯合物等食品。包括所有類型保健食品。
根據本揭示案的食品組合物可為嗜好食品或保健食品組合物。食品組合物在調配方面不特別受限制。舉例而言,可將食品組合物調配成錠劑、顆粒劑、粉末劑、液體(諸如飲品)、焦糖、凝膠、棒等。熟習此項技術者可取決於使用目的,藉由混合活性成分與技術中所常用的成分輕易製備食品組合物。當與其他成分一起使用時,可提供協同效果。
決定根據本揭示案的食品組合物中的活性成分之給藥劑量處於熟習此項技術者之水平內。舉例而言,每日給藥劑量可為0.1-5000mg/kg/日,更特定言之為50-500mg/kg/日,但並不受限於此。給藥劑量可取決於各種因素變化,該等因素包括受試者之年齡及身體狀態、併發症之存在等。
舉例而言,根據本揭示案的食品組合物可為各種食品(諸如口香糖、焦糖、糖果、速凍甜點、糖果甜點等)、飲品(諸如軟飲、礦泉水、酒精飲料等)或保健功能性食品(諸如維生素、礦物質等)形式。
另外,根據本揭示案的食品組合物可含有各種營養
素、維生素、礦物質(電解質)、合成或天然口味、著色劑、增量劑(乳酪、巧克力等)、果膠酸及其鹽、褐藻酸及其鹽、有機酸、保護性膠體增稠劑、pH調節劑、穩定劑、防腐劑、甘油、酒精、碳酸飲品中所使用之碳酸化劑等。此外,根據本揭示案的功能性食品組合物可含有用於製備果汁飲料及植物飲料的天然果汁及果肉。可單獨或組合添加該等成分。該等添加劑之混合比例不太重要。大體而言,以組合物之100重量%計,本揭示案中可含有約0-20重量%量的添加劑。
在下文中,將經由實例及測試實例詳細描述本揭示案。然而,以下實例及測試實例僅出於說明性目的,且將對熟習此項技術者顯而易見的是本揭示案之範疇不受限於該等實例及測試實例。
又,將對熟習此項技術者顯而易見的是可在不脫離本揭示案之範疇的情況下在隨附申請專利範圍之範疇內產生各種變化及修改。
收穫新鮮人參果及從中移除籽。藉由日曬乾燥或熱風乾燥乾燥人參果之果肉及果皮來製備經乾燥之人參果。
在將3L之乙醇添加至1kg之經乾燥之人參果中後,接著在室溫下回流萃取4小時,於45℃減壓過濾及濃縮,獲得300g之人參果萃取物。
收穫新鮮人參(Panax ginseng C.A.Meyer)之果實及從中移除籽。隨後,混合人參果之汁液、果肉及果皮。在將3L之乙醇添加至1kg之所得混合物中後,接著在室溫下回流萃取4小時,於45℃減壓過濾及濃縮,獲得30g之人參果萃取物。
用與實例1相同的方法製備人參根部萃取物,不同之處在於使用人參根部而不是人參果。
在將3L之乙醇添加至1kg之經乾燥之人參根部(4年生)中後,接著在室溫下回流萃取4小時,於45℃減壓過濾及濃縮,獲得300g之紅參果實萃取物。
用醚處理實例1及實例2之人參果萃取物及對照實例1之人參根部萃取物以移除油溶性組份及使用丁醇(BuOH)從中萃取粗皂素。隨後,藉由HPLC分析人參皂苷組合物。第1圖及表1展示結果。
從第1圖及表1中可看出,實例1及實例2中所製
備之人參果萃取物含有比對照實例1所製備之人參根部萃取物多出約2倍之粗皂素。
原人參二醇(PD)人參皂苷Rb1、Rb2、Rc及Rd與原人參三醇(PT)人參皂苷Re、Rg1及Rg2之比率分別為0.73、0.69及3.23。換言之,人參果及人參根部中所含有的人參皂苷展示出相反組合物及含量。詳言之,人參果萃取物與人參根部萃取物相比含有多出約9倍之人參皂苷Re。
由於作為「果實」的實例1及實例2中所製備之人參果萃取物之特徵化與人參根部不同,分析包括維生素在內的礦物質成分之組合物。表2中展示結果。
從表2中可看出,根據本揭示案的人參果富含與人參根部不同之包括維生素在內的16種礦物質。
因此,已證實,根據本揭示案的人參果含有更多人
參皂素且具有當人參根部相比時相反的皂素組合物。又,已證實,人參果富含與人參根部不同之包括維生素在內的16種礦物質。另外,從人參果處獲得之萃取物與從新鮮人參果處獲得之萃取物具有幾乎相同的組合物。因此,認為具有類似組合物的兩種萃取物將提供相同效果,如以下測試實例中所論證的。
定量分析實例1中所製備之人參果萃取物中所含有的花青素組份。
使用花青素試劑盒(氯化矢車菊色素(cyanidin chloride)、氯化飛燕草色素(delphinidin chloride)、氯化錦葵色素(malvidin chloride)、氯化天竺葵色素苷(pelargonin chloride))、矢車菊色素衍生物試劑盒(氯化矢車菊色素、氯化青色素(cyanine chloride)、氯化矢車菊素半乳糖苷(idein chloride)、氯化花青素鼠李葡萄糖苷(keracyanin chloride)、氯化矢車菊素葡萄糖苷(kuromanin chloride))及標準氯化天竺葵色素(pelargonidin chloride)及氯化牽牛花色素(petunidin chloride)定量分析人參果之花青素。表3中展示結果。
從表3中可看出,測定氯化錦葵色素、氯化矢車菊素半乳糖苷、氯化天竺葵色素苷及氯化花青素鼠李葡萄糖苷之含量分別為12.17、2.36、8.28及3.29ppm及四種成分之總和為26.1ppm。因此,已證實人參果富含花青素。
美國精神病學會(American Psychiatric Association)針對經前症候群給出以下診斷標準。
根據標準,選擇滿足以下11項中的至少5項及前4項中的至少1項的女性進行測試。
(1)情緒快速變化;突如其來的悲傷、憤怒或暴怒
(2)持續嚴重憤怒及不安
(3)不安及緊張
(4)抑鬱及絕望
(5)對日常生活不感興趣
(6)疲勞或低能量
(7)注意力不集中
(8)食欲變化
(9)睡眠紊亂
(10)情緒控制困難
(11)乳房脹痛、頭痛、水腫、肌肉或關節疼痛及重量增加
基於測試實例1之結果,向測試群組施予含有根據本揭示案之人參果萃取物的組合物及使用調查表評估給藥前與給藥後經前症候群及經痛之症狀的變化。
製備含有100重量%之實例1之人參果萃取物及對照實例2之紅參萃取物的350mg錠劑用於測試。使用桌上型錠劑製成器(Erweka,德國)。
根據診斷標準從48位生育年齡(20歲至50歲)女性中選擇40位女性。將該等女性分成4個群組:亦即,未給藥群組、紅參群組、人參皂苷Re群組及人參果群組。每個群組由10個對象組成。
要求紅參群組服用含紅參錠劑4周,每日兩次,每次兩粒錠劑。換言之,向該群組施予1400mg/日之紅參萃取物。
要求人參皂苷Re群組服用含有人參皂苷Re作為活性成分的錠劑,每日兩次,每次兩粒錠劑。錠劑製備為使得每日施予240mg之人參皂苷Re及1160mg之糊精(每粒錠劑60mg之人參皂苷Re及290mg之糊精)。基於第1圖所示之分析結果決定人參皂苷Re之含量以便比較人參果萃取物與僅所含有的人參皂苷Re對改良經前症候群及經痛之效果。
要求人參果群組服用含人參果萃取物的錠劑4周,每日兩次,每次兩粒錠劑。換言之,向該群組施予1400mg/日之人參果萃取物。
首先在月經後要求40位女性回答調查表,及在未給藥、施予紅參萃取物或人參果萃取物後,在下一月經結束後(約4周以後)回答調查表。藉由監測基於調查表的總得分變化評估經前症候群之症狀的改良。對於每一項給定一分。
表4中展示總得分的變化及表5中給出感受到經前
症候群之症狀的女性人數。此等情況亦展示於第2圖中(N=40)。
從表4至表5及第2圖可看出,施用人參果萃取物的受試者所給出的總得分顯著減少40%,與其他群組之彼等不同。又,在人參果群組中,感受到經前症候群之症狀的受試者數目從10個減少至5個,減少50%。因此,已證實,人參果萃取物對於緩解或改良經前症候群非常有效。
詳言之,人參果萃取物展現出與紅參萃取物或僅人參果萃取物中所包括的人參皂苷Re相比對緩解或改良經前症候群及經痛更優之效果。因此,已證實,人參果萃取物本身展現出與類似量之人參皂苷Re相比對緩解或改良經前症候群更優之效果。
在下文中,將經由調配實例詳細描述本揭示案。然而,以下調配實例僅出於說明性目的且將對熟習此項技術者
顯而易見的是本揭示案之範疇不受限於該等調配實例。
當製備實例1之人參果萃取物時,將該人參果萃取物濃縮至60重量%或更高之固體含量及隨後在低溫下熟化以獲得100重量%之液態人參果萃取物。
混合110mg之實例1之人參果萃取物、0.8mg之棕櫚油、0.48mg之氫化植物油、2.4mg之黃色蜂蠟及3.6mg之卵磷脂,並根據常用方法填充於軟膠囊中。
混合160mg之實例1之人參果萃取物、200mg之葡萄糖及196mg之糊精,使用流化床乾燥器製成顆粒狀,在添加7mg之糖酯後,製備成錠劑。
混合0.9g之實例1之人參果萃取物、0.3g之糖、1.91g之澱粉及0.56g之甘油,並製備成丸劑。
混合160mg之實例1之人參果萃取物、200mg之葡萄糖及196mg之糊精,使用流化床乾燥器製成顆粒狀及填充於小袋中。
混合110mg之實例1之人參果萃取物、10g之葡萄糖及2g之檸檬酸,並在添加188g之純水後以每瓶200mL填充於瓶中。從而,在90℃對所製備之飲品殺菌2-3小時。
根據常用方法用表6中所描述之組合物製備保健功能性食品。
作為特定實例給出維生素及礦物質之上述含量,但含量可根據需要而變化。
根據常用方法用表7中所描述之組合物製備口香糖。
根據常用方法用表8中所描述之組合物製備糖果。
將5重量%之實例1之人參果萃取物添加至100重量%之麵粉。使用所得混合物製備麵包、蛋糕、餅乾、蘇打餅乾及麵條。
將5-10重量%之實例1之人參果萃取物添加至100重量%之牛奶中,並使用所得混合物製備各種乳製品(諸如黃油及冰淇淋)。
根據已知方法預膠凝化糙米、大麥、糯米及薏苡及隨後經乾燥及粉碎至60篩孔大小之粉末。又,根據已知方法
蒸汽處理黑豆、黑芝麻及野生芝麻及隨後經乾燥及粉碎至60篩孔大小之粉末。如表9中所描述將穀物及籽與實例1之人參果萃取物混合。
根據常用方法用表10中所描述之組合物製備保健飲品。
根據常用方法,在85℃下加熱的同時混合上述成分並加熱約1小時。對所得溶液過濾及殺菌。
Claims (10)
- 一種用於緩解經前症候群或經痛的組合物,該組合物包含人參果萃取物作為活性成分,該人參果萃取物包含人參皂苷Re、維生素、礦物質及花青素,其中該人參果萃取物為人參果在室溫下回流的減壓濃縮乙醇萃取物。
- 如請求項1所述之組合物,其中以該萃取物之總重量計,該礦物質包含以下之一或更多者:至少4000mg/100g之鉀、至少600mg/100g之鈣、至少40mg/100g之鐵、至少150mg/100g之磷、至少250mg/100g之鎂及至少140mg/100g之鋅。
- 如請求項1所述之組合物,其中以該萃取物之總重量計,該維生素包含以下之一或更多者:至少150μg/100g之維生素A、至少8mg/100g之維生素B1、至少5mg/100g之維生素B2、至少8mg/100g之維生素B6、至少3mg/100g之維生素C、至少180μg/100g之維生素K、至少3.5mg/100g之菸鹼酸、至少4mg/100g之泛酸及至少250μg/100g之葉酸。
- 如請求項1所述之組合物,其中以該萃取物之總重量計,該組合物包含至少20ppm之該花青素。
- 如請求項1所述之組合物,其中以該萃取物之總重量計,該組合物包含5-30重量%之人參皂苷Re。
- 如請求項1所述之組合物,其中該人參果萃取物具有0.1-1.5之原人參二醇(PD)人參皂苷對原人參三醇(PT)人參皂苷的重量比率(PD/PT)。
- 如請求項1所述之組合物,其中以該組合物之總重量計,該組合物包含0.01-100重量%之含有該Re的人參果萃取物。
- 如請求項1所述之組合物,其中以該人參果萃取物之總重量計,該人參果萃取物包含至少20重量%之粗皂素。
- 如請求項1至8中任一項所述之組合物,其中該組合物係一醫藥組合物。
- 如請求項1至8中任一項所述之組合物,其中該組合物係一食品組合物。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
??10-2013-0078238 | 2013-07-04 | ||
KR20130078238 | 2013-07-04 | ||
??10-2014-0052770 | 2014-04-30 | ||
KR1020140052770A KR102262306B1 (ko) | 2013-07-04 | 2014-04-30 | 월경 전기 증후군 및 월경통 완화의 기능을 갖는 조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW201534317A TW201534317A (zh) | 2015-09-16 |
TWI648057B true TWI648057B (zh) | 2019-01-21 |
Family
ID=52477280
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW103122873A TWI648057B (zh) | 2013-07-04 | 2014-07-02 | 用於緩解經前症候群以及經痛之組合物 |
Country Status (8)
Country | Link |
---|---|
US (1) | US10342836B2 (zh) |
EP (1) | EP3017821B1 (zh) |
JP (1) | JP6404339B2 (zh) |
KR (1) | KR102262306B1 (zh) |
CN (1) | CN105358168B (zh) |
HK (1) | HK1215172A1 (zh) |
TW (1) | TWI648057B (zh) |
WO (1) | WO2015002391A1 (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102359433B1 (ko) * | 2015-03-13 | 2022-02-09 | (주)아모레퍼시픽 | 암백신 조성물 및 키트 |
KR102336131B1 (ko) * | 2015-04-02 | 2021-12-07 | (주)아모레퍼시픽 | 인삼 열매 추출물을 함유하는 난소 노화 개선용 조성물 |
CN106975014B (zh) * | 2017-02-28 | 2021-02-02 | 吉林农业大学 | 一种人参果花青素的制备方法及用途 |
KR101847497B1 (ko) | 2017-03-23 | 2018-04-10 | 우혜진 | 능이버섯 추출물을 유효성분으로 함유하는 부인과 질환의 예방 또는 치료용 약학적 조성물 |
JP2022545960A (ja) | 2019-08-26 | 2022-11-01 | ピリオド ピル ベーフェー | 月経周期性症状の治療 |
CN111686230A (zh) * | 2020-07-15 | 2020-09-22 | 徐文华 | 一种补阳生发组合物、制备方法和用途 |
CN114159450B (zh) * | 2020-09-10 | 2023-10-27 | 上海交通大学 | 原人参二醇类化合物在治疗疼痛和成瘾物质躯体依赖、精神依赖和成瘾的用途 |
JP7226727B1 (ja) | 2022-12-05 | 2023-02-21 | 株式会社バリバ | 経口組成物 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20110089036A (ko) * | 2010-01-29 | 2011-08-04 | (주)그린바이오싸이언스 | 불임증 개선을 위한 기능성 식품조성물 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4945103A (en) | 1989-01-17 | 1990-07-31 | Michael Cohen | Method of treating pre-menstrual syndrome |
KR970025616A (ko) * | 1995-11-13 | 1997-06-24 | 나승열 | 인삼 진세노사이드를 함유하는 항통증제 |
US20020136785A1 (en) | 2000-11-07 | 2002-09-26 | Chun-Su Yuan | Ginseng berry extracts and pharmaceutical compositions from ginseng berry for the treatment of type 2 diabetes and obesity |
US20040101934A1 (en) | 2001-02-27 | 2004-05-27 | Choe Yun Seok | Peptide derived from yeast having activities as anti-tsress, anti-fatigue and brain neurotrophic factor and relaxing premenstrual syndrome and menstrual pain, and preparing process thereof |
KR100497895B1 (ko) * | 2002-12-05 | 2005-06-29 | 홍림통산(주) | 인삼의 유산균 발효물, 그를 함유하는 인삼 요구르트 및그에 이용되는 유산균 균주 |
CN100515478C (zh) | 2004-01-02 | 2009-07-22 | 秦皇岛市山海关制药厂 | 治疗经前期综合征的中药组合物 |
US7372493B2 (en) * | 2004-07-12 | 2008-05-13 | Micron Technology, Inc. | Column-wise clamp voltage driver for suppression of noise in an imager |
KR20080104600A (ko) | 2007-05-28 | 2008-12-03 | (주)아모레퍼시픽 | 인삼 열매 추출물을 함유하는 혈행촉진, 혈관신생촉진, 및허혈성 심질환 치료용 조성물 |
KR101614110B1 (ko) | 2008-11-28 | 2016-04-21 | (주)아모레퍼시픽 | 동맥경화 예방 또는 치료용 조성물 |
KR20110104259A (ko) | 2010-03-16 | 2011-09-22 | 성인환 | 인삼열매를 포함하는 캡슐제 및 이의 제조방법 |
CN101940350B (zh) * | 2010-07-05 | 2012-09-19 | 赵景辉 | 一种具有镇静、安神作用的人参果冲剂及其制备工艺 |
KR101221417B1 (ko) | 2010-07-08 | 2013-01-11 | 세명대학교 산학협력단 | 인삼 열매 추출물을 포함하는 모발 성장 촉진용 조성물 |
KR101314762B1 (ko) | 2011-09-27 | 2013-10-04 | 주식회사 한국지네틱팜 | 인삼열매 또는 씨앗을 발효시켜 추출한 발효물의 제조방법 및 이를 이용한 발효식품 |
CN102727548A (zh) * | 2012-07-03 | 2012-10-17 | 吉林省宏久生物科技股份有限公司 | 一种人参茎叶总皂苷提取新技术及方法 |
WO2014163402A1 (ko) | 2013-04-02 | 2014-10-09 | 주식회사 아모레퍼시픽 | 인삼 열매 추출물을 함유하는 여성 건강 및 삶의 질 개선용 조성물 |
-
2014
- 2014-04-30 KR KR1020140052770A patent/KR102262306B1/ko active IP Right Grant
- 2014-06-19 EP EP14819802.1A patent/EP3017821B1/en active Active
- 2014-06-19 US US14/902,392 patent/US10342836B2/en active Active
- 2014-06-19 WO PCT/KR2014/005392 patent/WO2015002391A1/ko active Application Filing
- 2014-06-19 JP JP2016523631A patent/JP6404339B2/ja active Active
- 2014-06-19 CN CN201480038214.6A patent/CN105358168B/zh active Active
- 2014-07-02 TW TW103122873A patent/TWI648057B/zh active
-
2016
- 2016-03-17 HK HK16103163.7A patent/HK1215172A1/zh unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20110089036A (ko) * | 2010-01-29 | 2011-08-04 | (주)그린바이오싸이언스 | 불임증 개선을 위한 기능성 식품조성물 |
Also Published As
Publication number | Publication date |
---|---|
CN105358168A (zh) | 2016-02-24 |
JP2016523897A (ja) | 2016-08-12 |
US10342836B2 (en) | 2019-07-09 |
JP6404339B2 (ja) | 2018-10-10 |
HK1215172A1 (zh) | 2016-08-19 |
EP3017821A1 (en) | 2016-05-11 |
TW201534317A (zh) | 2015-09-16 |
EP3017821A4 (en) | 2017-03-15 |
KR102262306B1 (ko) | 2021-06-09 |
EP3017821B1 (en) | 2019-02-20 |
US20160367614A1 (en) | 2016-12-22 |
KR20150005430A (ko) | 2015-01-14 |
WO2015002391A1 (ko) | 2015-01-08 |
CN105358168B (zh) | 2021-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI648057B (zh) | 用於緩解經前症候群以及經痛之組合物 | |
KR100479803B1 (ko) | 약효가 증가된 특수가공처리 인삼 추출물을 함유하는뇌졸증의 예방 및 치료를 위한 조성물 | |
CN103747794A (zh) | 用于预防或治疗特应性皮炎的芫花提取物以及含有该提取物的部位或从该提取物分离的化合物作为活性成分的药物组合物 | |
KR101184666B1 (ko) | 양성 체질의 생리 활성 증진용 조성물 | |
CN104688791A (zh) | 具有生物利用度提高的皂素的组合物 | |
US10675316B2 (en) | Composition for preventing and treating climacteric disorder containing extracts of Dendropanax morbifera LEV. as active ingredient | |
KR20060000488A (ko) | 인삼 또는 홍삼 추출물, 그의 유산균 발효물 및 그의장내세균 발효물로 이루어진 군으로부터 선택된 1종이상의 인삼 추출물 소양증 예방 및 치료제 조성물 | |
KR101336094B1 (ko) | 피부 개선용 건강기능식품 조성물 및 그 제조방법 | |
KR101067028B1 (ko) | 산나물 추출물을 함유하는 여성 폐경기 증후군 예방 및 치료용 조성물 | |
KR100688425B1 (ko) | 유효 성분으로 진세노시드 Rh2를 함유하는 뇌세포 보호조성물 | |
KR101525877B1 (ko) | 피부 주름 개선 및 피부 노화 방지를 위한 조성물 | |
KR101931226B1 (ko) | 결명자 추출물을 유효성분으로 포함하는 다낭성 난소 증후군 관련 질환의 예방, 개선 또는 치료용 조성물 | |
JP6182808B2 (ja) | ボタンボウフウ又はその抽出物を含む精子改善剤及び精液改善剤 | |
KR100759772B1 (ko) | 유효 성분으로 진세노시드 Rh2를 함유하는 뇌세포 보호조성물 | |
JP2004323439A (ja) | 血液粘性改善用組成物 | |
KR20100008220A (ko) | 버섯 및 생약 추출물을 포함하는 대장암 예방 및 치료용조성물 | |
KR20170014329A (ko) | 당나귀 추출물을 포함하는 건강기능식품 조성물 | |
KR102178967B1 (ko) | 갈화 발효 추출물을 포함하는 갱년기 증상의 예방 또는 치료용 조성물 | |
KR100456417B1 (ko) | 약효가 증가된 특수가공처리 인삼 추출물을 함유하는뇌졸증의 예방 및 치료를 위한 조성물 | |
TW202342083A (zh) | 用於預防、改善或治療肥胖症的包括作為活性成分的南非醉茄萃取物和西伯利亞菊萃取物的複合物(asc複合物)的組成物 | |
KR20150111096A (ko) | 생지황, 구기자, 침향, 복령, 인삼 및 꿀 혼합물을 유효성분으로 함유하는 남성 불임 예방 및 치료용 약학적 조성물 | |
KR20200113921A (ko) | 섬바디 추출물을 유효성분으로 함유하는 당뇨병의 예방 또는 치료용 약학적 조성물 및 건강 기능 식품 | |
KR20030080297A (ko) | 인삼으로부터 분리된 사포닌 유도체를 함유하는 알레르기질환의 예방 및 치료를 위한 조성물 | |
KR20170130081A (ko) | 천문동 추출물을 유효성분으로 함유하는 여성 호르몬 조절이상 질환의 예방 및 개선을 위한 조성물 | |
KR20100008218A (ko) | 홍삼 추출물을 함유한 대장암 예방 또는 치료용 조성물 |